MANH
VENTE TOTALE: 4 579 titres (~893 100,68 $ US)
- Insiders
- Clark Eric Andrew, Hollembaek Linda T.
- Total bought
- —
- Total sold
- $893,101
- Last activity
- 2026-08-11
- Last synced
-
2026-08-21 23:36:53
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-13
MANH exhibits genuinely strong financial fundamentals — high ROIC/ROE, expanding margins, and robust cash flow generation — yielding a composite health score of 82.5, but the event-driven overlay is decisively negative…
The first sentence of the analysis written for MANH on 2026-08-13 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 55.7% | 54.2% | 53.0% | 52.4% | 53.9% | |
| Ebit Margin | 26.4% | 25.6% | 23.0% | 20.6% | 20.2% | |
| Ebitda Margin | 27.0% | 26.2% | 23.6% | 21.5% | 21.4% | |
| Operating Profit Margin | 26.1% | 25.1% | 22.6% | 19.9% | 20.2% | |
| Pretax Profit Margin | 26.4% | 25.6% | 23.0% | 20.6% | 20.2% | |
| Continuous Operations Profit Margin | 20.3% | 20.9% | 19.0% | 16.8% | 16.6% | |
| Net Profit Margin | 20.3% | 20.9% | 19.0% | 16.8% | 16.6% | |
| Bottom Line Profit Margin | 20.3% | 20.9% | 19.0% | 16.8% | 16.6% | |
| Current Ratio | 1.279 | 1.257 | 1.310 | 1.316 | 1.640 | |
| Quick Ratio | 1.279 | 1.257 | 1.310 | 1.316 | 1.640 | |
| Solvency Ratio | 0.431 | 0.490 | 0.461 | 0.395 | 0.410 | |
| Cash Ratio | 0.721 | 0.665 | 0.740 | 0.714 | 1.059 | |
| Price To Earnings Ratio | 47.613 | 75.910 | 75.287 | 59.220 | 89.362 | |
| Price To Earnings Growth Ratio | 21.188 | 3.101 | 1.905 | 3.324 | 3.309 | |
| Forward Price To Earnings Growth Ratio | 21.188 | 3.101 | 1.905 | 3.324 | 3.309 | |
| Price To Earnings Diluted Ratio | 48.142 | 76.991 | 76.355 | 59.803 | 90.401 | |
| Price To Earnings Diluted Growth Ratio | 18.775 | 3.147 | 1.962 | 3.318 | 3.415 | |
| Price To Book Ratio | 33.297 | 55.383 | 47.831 | 33.598 | 39.359 | |
| Price To Sales Ratio | 9.692 | 15.893 | 14.332 | 9.934 | 14.865 | |
| Price To Free Cash Flow Ratio | 28.022 | 57.859 | 55.118 | 44.036 | 54.453 | |
| Price To Operating Cash Flow Ratio | 26.910 | 56.157 | 54.060 | 42.421 | 53.272 | |
| Debt To Assets Ratio | 0.134 | 0.063 | 0.026 | 0.025 | 0.043 | |
| Debt To Equity Ratio | 0.357 | 0.160 | 0.064 | 0.062 | 0.092 | |
| Debt To Capital Ratio | 0.263 | 0.138 | 0.060 | 0.058 | 0.085 | |
| Long Term Debt To Capital Ratio | 0.151 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 2.667 | 2.533 | 2.420 | 2.514 | 2.153 | |
| Working Capital Turnover Ratio | 9.388 | 9.641 | 8.718 | 5.920 | 4.478 | |
| Operating Cash Flow Ratio | 0.854 | 0.737 | 0.673 | 0.569 | 0.744 | |
| Operating Cash Flow Sales Ratio | 0.360 | 0.283 | 0.265 | 0.234 | 0.279 | |
| Free Cash Flow Operating Cash Flow Ratio | 0.960 | 0.971 | 0.981 | 0.963 | 0.978 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | 3.466 | 6.172 | 13.915 | 12.771 | 7.997 | |
| Capital Expenditure Coverage Ratio | 25.197 | 34.006 | 52.055 | 27.270 | 46.111 | |
| Dividend Paid And Capex Coverage Ratio | 25.197 | 34.006 | 52.055 | 27.270 | 46.111 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 35.126 | 59.858 | 59.508 | 44.960 | 67.785 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 55.7% | ▲1.5% | ▲1.9% |
| Ebit Margin | 26.4% | ▲0.8% | ▲3.3% |
| Ebitda Margin | 27.0% | ▲0.8% | ▲3.1% |
| Operating Profit Margin | 26.2% | ▲1.1% | ▲3.4% |
| Pretax Profit Margin | 26.4% | ▲0.8% | ▲3.3% |
| Continuous Operations Profit Margin | 20.3% | ▼-0.6% | ▲1.6% |
| Net Profit Margin | 20.3% | ▼-0.6% | ▲1.6% |
| Bottom Line Profit Margin | 20.3% | ▼-0.6% | ▲1.6% |
| Current Ratio | 1.280 | ▲0.022 | ▼-0.081 |
| Quick Ratio | 1.280 | ▲0.022 | ▼-0.081 |
| Solvency Ratio | 0.431 | ▼-0.059 | ▼-0.006 |
| Cash Ratio | 0.721 | ▲0.056 | ▼-0.059 |
| Price To Earnings Ratio | 47.613 | ▼-28.297 | ▼-21.866 |
| Price To Earnings Growth Ratio | 21.188 | ▲18.086 | ▲14.622 |
| Forward Price To Earnings Growth Ratio | 21.188 | ▲18.086 | ▲14.622 |
| Price To Earnings Diluted Ratio | 48.142 | ▼-28.850 | ▼-22.197 |
| Price To Earnings Diluted Growth Ratio | 18.775 | ▲15.629 | ▲12.652 |
| Price To Book Ratio | 33.297 | ▼-22.087 | ▼-8.597 |
| Price To Sales Ratio | 9.692 | ▼-6.202 | ▼-3.251 |
| Price To Free Cash Flow Ratio | 28.022 | ▼-29.837 | ▼-19.875 |
| Price To Operating Cash Flow Ratio | 26.910 | ▼-29.247 | ▼-19.654 |
| Debt To Assets Ratio | 0.134 | ▲0.071 | ▲0.076 |
| Debt To Equity Ratio | 0.357 | ▲0.197 | ▲0.210 |
| Debt To Capital Ratio | 0.263 | ▲0.125 | ▲0.142 |
| Long Term Debt To Capital Ratio | 0.151 | ▲0.151 | ▲0.121 |
| Financial Leverage Ratio | 2.667 | ▲0.134 | ▲0.209 |
| Working Capital Turnover Ratio | 9.388 | ▼-0.253 | ▲1.759 |
| Operating Cash Flow Ratio | 0.854 | ▲0.117 | ▲0.139 |
| Operating Cash Flow Sales Ratio | 0.360 | ▲0.077 | ▲0.076 |
| Free Cash Flow Operating Cash Flow Ratio | 0.960 | ▼-0.010 | ▼-0.010 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | 3.466 | ▼-2.706 | ▼-5.398 |
| Capital Expenditure Coverage Ratio | 25.197 | ▼-8.809 | ▼-11.731 |
| Dividend Paid And Capex Coverage Ratio | 25.197 | ▼-8.809 | ▼-11.731 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 35.126 | ▼-24.732 | ▼-18.321 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $10.48B | $16.57B | $13.31B | $7.62B | $9.87B | |
| Enterprise value | $10.26B | $16.35B | $13.06B | $7.41B | $9.62B | |
| EV / Sales | 9.49x | 15.68x | 14.06x | 9.66x | 14.50x | |
| EV / Op. cash flow | 26.35x | 55.42x | 53.03x | 41.24x | 51.97x | |
| EV / Free cash flow | 27.44x | 57.10x | 54.07x | 42.81x | 53.12x | |
| EV / EBITDA | 35.13x | 59.86x | 59.51x | 44.96x | 67.78x | |
| Net debt / EBITDA | -0.74x | -0.80x | -1.15x | -1.28x | -1.69x | |
| Current ratio | 1.28x | 1.26x | 1.31x | 1.32x | 1.64x | |
| Income quality | 1.77x | 1.35x | 1.39x | 1.39x | 1.68x | |
| Graham number | $21 | $20 | $17 | $13 | $12 | |
| Graham net-net | -$1 | -$1 | $0 | $0 | $1 | |
| Tax burden | 76.9% | 81.8% | 82.6% | 81.6% | 82.4% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $127.4M | $103.0M | $113.3M | $99.8M | $159.4M | |
| Invested capital | $263.2M | $227.1M | $208.9M | $192.6M | $262.8M | |
| Return on assets | 26.2% | 28.8% | 26.2% | 22.6% | 20.5% | |
| Operating ROA | 35.4% | 36.6% | 33.8% | 27.5% | 26.7% | |
| Return on tangible assets | 28.3% | 31.4% | 28.9% | 25.4% | 23.1% | |
| Return on equity | 69.9% | 73.0% | 63.5% | 56.9% | 44.1% | |
| Return on invested capital | 56.7% | 59.9% | 56.4% | 48.9% | 38.1% | |
| Return on capital employed | 73.7% | 73.2% | 68.3% | 60.0% | 46.2% | |
| Earnings yield | 2.1% | 1.3% | 1.3% | 1.7% | 1.1% | |
| Free cash flow yield | 3.6% | 1.7% | 1.8% | 2.3% | 1.8% | |
| Capex / Op. cash flow | 4.0% | 2.9% | 1.9% | 3.7% | 2.2% | |
| Capex / Depreciation | 244.7% | 137.7% | 82.2% | 98.9% | 50.7% | |
| Capex / Sales | 1.4% | 0.8% | 0.5% | 0.9% | 0.6% | |
| SG&A / Sales | 16.2% | 15.9% | 16.8% | 17.9% | 19.0% | |
| R&D / Sales | 13.4% | 13.2% | 13.7% | 14.6% | 14.7% | |
| Stock comp / Sales | 10.3% | 8.9% | 7.7% | 7.7% | 6.5% | |
| Intangibles / Total assets | 7.4% | 8.2% | 9.2% | 10.9% | 11.5% | |
| Days sales outstanding | 72d | 74d | 72d | 80d | 70d | |
| Days payables outstanding | 17d | 20d | 20d | 26d | 23d | |
| Operating cycle | 72d | 74d | 72d | 80d | 70d | |
| Cash conversion cycle | 56d | 53d | 51d | 54d | 46d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-36.7%EV / Sales ▼-39.5%EV / EBITDA ▼-41.3%EV / Op. cash flow ▼-29.062Earnings yield ▲+0.008Graham number ▲+0.863
Profitability
Return on equity ▼-0.031Return on assets ▼-0.026Return on invested capital ▼-0.032Return on capital employed ▲+0.005Operating ROA ▼-0.012Income quality ▲+0.420Tax burden ▼-0.049
Efficiency
Days sales outstanding ▼-1.310Days payables outstanding ▼-3.439Operating cycle ▼-1.310Cash conversion cycle ▲+2.129Capex / Sales ▲+0.006R&D / Sales ▲+0.002
Balance-sheet strength
Current ratio ▲+0.022Net debt / EBITDA ▲+0.059Working capital ▲+24465000.000Invested capital ▲+36152000.000Intangibles / Total assets ▼-0.008
Change over 5 years
Valuation
Market cap ▲+6.2%EV / Sales ▼-34.6%EV / EBITDA ▼-48.2%EV / Op. cash flow ▼-25.619Earnings yield ▲+0.010Graham number ▲+8.198
Profitability
Return on equity ▲+0.258Return on assets ▲+0.057Return on invested capital ▲+0.186Return on capital employed ▲+0.275Operating ROA ▲+0.087Income quality ▲+0.094Tax burden ▼-0.055
Efficiency
Days sales outstanding ▲+2.602Days payables outstanding ▼-6.514Operating cycle ▲+2.602Cash conversion cycle ▲+9.115Capex / Sales ▲+0.008R&D / Sales ▼-0.013
Balance-sheet strength
Current ratio ▼-0.360Net debt / EBITDA ▲+0.954Working capital ▼-31952000.000Invested capital ▲+455000.000Intangibles / Total assets ▼-0.041
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2025-01-13 | Rob Bresnahan | Sale | $1,001 - $15,000 |
| 2022-05-23 | Ro Khanna | Sale | $1,001 - $15,000 |
| 2022-02-17 | Ro Khanna | Purchase | $1,001 - $15,000 |
| 2019-06-24 | Donna Shalala | Sale (Full) | $1,001 - $15,000 |
Recent news
- 2026-08-14 MANH Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. – MANH NEW YORK, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).
- 2026-08-14 Chuck Royce''s Second Quarter 2026 13F: Catalyst Pharmaceuticals Reduction Leads Portfolio Shifts A Deep Dive into the Small-Cap Pioneer''s Latest Moves, Including a -0.42% Impact from Exiting a Major StakeCharles M. Royce, a pioneer of small-cap investing an
- 2026-08-13 Manhattan Associates Inc (MANH) Stock Up 4.3% and Still Undervalued -- GF Score: 91/100 On August 13, 2026, Manhattan Associates Inc (MANH) shares rose 4.3% to a current price of $200.92. This price is notably within a 52-week range of $119.06 to $
- 2026-08-11 MANH Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. – MANH NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH). If you currently own shares of Manhattan Associates stock, please visit the firm''s website at https://rosenlegal.com/submit-form/?case_id=35966 for more information.
- 2026-08-08 MANH Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. - MANH New York, Aug. 08, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).
- 2026-08-07 Manhattan Associates (MANH) Now Trades Above Golden Cross: Time to Buy? Manhattan Associates, Inc. (MANH) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, MANH''s 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
- 2026-08-07 Manhattan Associates (MANH) is a Top-Ranked Momentum Stock: Should You Buy? Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- 2026-08-05 MANH Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. – MANH NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH).
- 2026-08-02 Manhattan Associates, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. - MANH Manhattan Associates, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers o
- 2026-08-02 Manhattan Associates, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Manhattan Associates, Inc. - MANH NEW YORK, Aug. 2, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, continues to investigate potential breaches of fiduciary duties by the directors and officers of Manhattan Associates, Inc. (NASDAQ: MANH). If you currently own shares of Manhattan Associates stock, please visit the firm''s website at https://rosenlegal.com/submit-form/?case_id=35966 for more information.